Annals of Hematology

, Volume 82, Issue 12, pp 766–768 | Cite as

A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody

  • Dany Gholam
  • Jean-Marie Vantelon
  • Ahmad Al-Jijakli
  • Jean-Henri Bourhis
Case Report


Multicentric Castleman's disease (MCD) is a rare systemic lymphoproliferative disorder with too few patient series reported in the literature to have a clear idea about the etiology, outcome and the best treatment available. Systemic reactive amyloidosis is a very rare complication of MCD and its presence worsens the prognosis. We report a case of a 28-year-old patient with plasma-cell type, human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative MCD who responded to treatment with chemotherapy and the anti-CD20 monoclonal antibody, rituximab. Anti-CD20 therapy could be an interesting adjunctive treatment in MCD.


Anti-CD20 monoclonal antibody Multicentric Castleman's disease Secondary amyloidosis 



The authors are grateful to Ms. Lorna Saint Ange for editing.


  1. 1.
    Keller A, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683PubMedGoogle Scholar
  2. 2.
    Flendrig J, Schillings PHM (1969) Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl 12:119Google Scholar
  3. 3.
    Peterson B, Frizzera G (1993) Multicentric Castleman's disease. Semin Oncol 20:636–647PubMedGoogle Scholar
  4. 4.
    Chronowski G, Ha C, Wilder R et al (2001) Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 92:670–676CrossRefPubMedGoogle Scholar
  5. 5.
    Katano H, Sata T (1999) An attractive relation of human herpesvirus-8 with multicentric Castleman's disease. Intern Med 38:221–222PubMedGoogle Scholar
  6. 6.
    Hayashi M, Aoshiba K, Shimada M et al (1999) Kaposi's sarcoma-associated herpesvirus infection in the lung in multicentric Castleman's disease. Intern Med 38:279–282PubMedGoogle Scholar
  7. 7.
    Bowne W, Lewis J, Filippa D, et al (1999) The management of unicentric and multicentric Castleman's disease. Cancer 85:706–717PubMedGoogle Scholar
  8. 8.
    Andres E, Maloisel F (2000) Interferon-α as first-line therapy for treatment of multicentric Castleman's disease. Ann Oncol 11:1613–1614CrossRefPubMedGoogle Scholar
  9. 9.
    Rieu P, Droz D, Gessain A et al (1999) Retinoic acid for treatment of multicentric Castleman's disease. Lancet 354:1262–1263CrossRefPubMedGoogle Scholar
  10. 10.
    Nishimoto N, Sasai M, Shima Y, Nakagawa M et al (2000) Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56–61PubMedGoogle Scholar
  11. 11.
    Corbellino M, Bestetti G, Scalamogna C et al (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 12:3473–3475CrossRefGoogle Scholar
  12. 12.
    Suda T, Katano H, Delsol G, Kakiuchi C, Nakamura T et al (2001) HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int 51:671–679CrossRefPubMedGoogle Scholar
  13. 13.
    Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M et al (2002) Update on Kaposi's sarcoma and other HHV-8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2:344–352CrossRefPubMedGoogle Scholar
  14. 14.
    West KP, Morgan DR, Lauder I (1989) Angiofollicular lymph node hyperplasia with amyloidosis. Postgrad Med J 65:108–111PubMedGoogle Scholar
  15. 15.
    Ordi J, Grau JM, Junque A, Nomdeleu B, Palacin A, Cardesa A (1993) Secondary (AA) amyloidosis associated with Castleman's disease. Am J Clin Pathol 100:394–397PubMedGoogle Scholar
  16. 16.
    Miura A, Saro I, Suzuki C (1995) Fatal diarrhea in a patient with Castleman's disease associated with intestinal amyloidosis. Intern Med 34:1106–1109PubMedGoogle Scholar
  17. 17.
    Tanaka K, Horita M, Shibayama H, Seike M, Itoh Y et al (1995) Secondary amyloidosis associated with Castleman's disease. Intern Med 34:122–126PubMedGoogle Scholar
  18. 18.
    Funabiki K, Kaneko S, Terajima M, Tomita H, Kawano Y, Tomino Y (1998) A case of multicentric Castleman's disease associated with renal amyloidosis and pure red cell aplasia. Am J Nephrol 18:247–250PubMedGoogle Scholar
  19. 19.
    Altiparmak MR, Pamuk GE, Pamuk ON, Dogusoy G (2002) Secondary amyloidosis in Castleman's disease: review of the literature and report of a case. Ann Hematol 81:336–339CrossRefPubMedGoogle Scholar
  20. 20.
    Derici U, Arinsoy T, Ataoglu O, Bali M, Sindel S et al (2002) Localized Castleman's disease and nephrotic syndrome not responsive to resection plus colchicine therapy. Ann Hematol 81:399–401CrossRefPubMedGoogle Scholar
  21. 21.
    Sezer O, Eucker J, Schmid P, Possinger K (2000) New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol 79:1-6CrossRefPubMedGoogle Scholar
  22. 22.
    Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA (1999) Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 17:262–267PubMedGoogle Scholar
  23. 23.
    Van Eygen K, Zachee P, Maertens J, Vandenberghe P, Demuynck H, Verhoef G, Boogaerts A (1996) Treatment of primary amyloidosis with VAD combination chemotherapy results in improved survival. Blood 88(1):591aGoogle Scholar
  24. 24.
    Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone and melaphalan, prednisone and colchicine. N Engl J Med 336:1202–1207CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Dany Gholam
    • 1
    • 2
  • Jean-Marie Vantelon
    • 2
  • Ahmad Al-Jijakli
    • 2
  • Jean-Henri Bourhis
    • 2
  1. 1.Department of Hematology and OncologyHopital Paul BrousseVillejuifFrance
  2. 2.Department of HematologyInstitut Gustave-RoussyVillejuifFrance

Personalised recommendations